Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 1
2018 4
2019 1
2020 3
2021 2
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
[52Mn]Mn-BPPA-Trastuzumab: A Promising HER2-Specific PET Radiotracer.
Toàn NM, Vágner A, Nagy G, Ország G, Nagy T, Csikos C, Váradi B, Sajtos GZ, Kapus I, Szoboszlai Z, Szikra D, Trencsényi G, Tircsó G, Garai I. Toàn NM, et al. Among authors: vagner a. J Med Chem. 2024 May 23;67(10):8261-8270. doi: 10.1021/acs.jmedchem.4c00344. Epub 2024 May 1. J Med Chem. 2024. PMID: 38690886
Boosting Bismuth(III) Complexation for Targeted α-Therapy (TAT) Applications with the Mesocyclic Chelating Agent AAZTA.
Horváth D, Vágner A, Szikra D, Trencsényi G, Demitri N, Guidolin N, Maiocchi A, Ghiani S, Travagin F, Giovenzana GB, Baranyai Z. Horváth D, et al. Among authors: vagner a. Angew Chem Int Ed Engl. 2022 Oct 24;61(43):e202207120. doi: 10.1002/anie.202207120. Epub 2022 Sep 29. Angew Chem Int Ed Engl. 2022. PMID: 36073561 Free PMC article.
Synthesis, Physicochemical, Labeling and In Vivo Characterization of 44Sc-Labeled DO3AM-NI as a Hypoxia-Sensitive PET Probe.
Szücs D, Csupász T, Szabó JP, Kis A, Gyuricza B, Arató V, Forgács V, Vágner A, Nagy G, Garai I, Szikra D, Tóth I, Trencsényi G, Tircsó G, Fekete A. Szücs D, et al. Among authors: vagner a. Pharmaceuticals (Basel). 2022 May 26;15(6):666. doi: 10.3390/ph15060666. Pharmaceuticals (Basel). 2022. PMID: 35745585 Free PMC article.
In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [52Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model.
Csikos C, Vágner A, Nagy G, Kálmán-Szabó I, Szabó JP, Ngo MT, Szoboszlai Z, Szikra D, Krasznai ZT, Trencsényi G, Garai I. Csikos C, et al. Among authors: vagner a. Diagnostics (Basel). 2023 Jan 8;13(2):236. doi: 10.3390/diagnostics13020236. Diagnostics (Basel). 2023. PMID: 36673046 Free PMC article.
In Vivo evaluation of newly synthesized 213Bi-conjugated alpha-melanocyte stimulating hormone (α-MSH) peptide analogues in melanocortin-1 receptor (MC1-R) positive experimental melanoma model.
Kálmán-Szabó I, Képes Z, Fekete A, Vágner A, Nagy G, Szücs D, Gyuricza B, Arató V, Varga J, Kárpáti L, Garai I, Mándity I, Bruchertseifer F, Elek J, Szikra D, Trencsényi G. Kálmán-Szabó I, et al. Among authors: vagner a. J Pharm Biomed Anal. 2023 May 30;229:115374. doi: 10.1016/j.jpba.2023.115374. Epub 2023 Mar 28. J Pharm Biomed Anal. 2023. PMID: 37001274 Free article.
Evaluation of the therapeutic efficacy of 213Bi-labelled DOTA-conjugated alpha-melanocyte stimulating hormone peptide analogues in melanocortin-1 receptor positive preclinical melanoma model.
Csikos C, Képes Z, Fekete A, Vágner A, Nagy G, Gyuricza B, Arató V, Kárpáti L, Mándity I, Bruchertseifer F, Halmos G, Szikra D, Trencsényi G. Csikos C, et al. Among authors: vagner a. Int J Pharm. 2023 Sep 25;644:123344. doi: 10.1016/j.ijpharm.2023.123344. Epub 2023 Aug 25. Int J Pharm. 2023. PMID: 37634663 Free article.
20 results